Reviews Zevalin


No reviews yet.

Zevalin Drug Description
ZEVALIN®
(ibritumomab tiuxetan) Injection for Intravenous Use

WARNING
SERIOUS INFUSION REACTIONS, PROLONGED AND SEVERE CYTOPENIAS,
and SEVERE CUTANEOUS AND MUCOCUTANEOUS REACTIONS
Serious Infusion Reactions: Deaths have occurred within 24 hours of rituximab
infusion, an essential component of the Zevalin therapeutic regimen. These fatalities
were associated with hypoxia, pulmonary infiltrates, acute respiratory distress
syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock.
Most (80%) fatalities
occurred with the first rituximab infusion [see WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS]. Discontinue rituximab, In-111
Zevalin, and Y-90 Zevalin infusions in patients who develop severe infusion
reactions.
Prolonged and Severe Cytopenias: Y-90 Zevalin administration results in
severe and prolonged cytopenias in most patients. Do not administer the Zevalin
therapeutic regimen to patients with ≥ 25% lymphoma marrow involvement and/or
impaired bone marrow reserve [see WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS].
Severe Cutaneous and Mucocutaneous Reactions: Severe cutaneous and mucocutaneous
reactions, some fatal, can occur with the Zevalin therapeutic regimen. Discontinue
rituximab, In-111 Zevalin, and Y-90 Zevalin infusions in patients experiencing
severe cutaneous or mucocutaneous reactions [see WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS].
Dosing: The dose of Y-90 Zevalin should not exceed 32.0 mCi (1184 MBq).
Do not administer Y-90 Zevalin to patients with altered biodistribution as determined
by imaging with In-111 Zevalin [see DOSAGE AND ADMINISTRATION].

DRUG DESCRIPTION



What are the possible side effects of ibritumomab (In-111 Zevalin, Y-90 Zevalin)?

Some people receiving an ibritumomab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, sweaty, itchy, or have a fast heartbeat, trouble breathing, chest pain or heavy feeling, or pain spreading to the arm or shoulder. These reactions can occur during the injection or within 24 hours afterward.
Get emergency medical help if you have any of these signs of an allergic...
Read All Potential Side Effects for Zevalin »




Zevalin (ibritumomab tiuxetan) is the immunoconjugate resulting from a stable
thiourea covalent bond between the monoclonal antibody ibritumomab and the linker-chelator
tiuxetan [N-[2-bis(carboxymethyl)amino]-3-(pisothiocyanatophenyl)- propyl]-[N-[2-bis(carboxymethyl)amino]-2-(methyl)-
ethyl]glycine. This linker-chelator provides a high affinity, conformationally
restricted chelation site for Indium-111 or Yttrium-90. The approximate molecular
weight of ibritumomab tiuxetan is 148 kD. The antibody moiety of Zevalin is
ibritumomab, a murine IgG1 kappa monoclonal antibody directed against the CD20
antigen.
Ibritumomab tiuxetan is a clear, colorless, sterile, pyrogen-free, preservativefree
solution that may contain translucent particles. Each single-use vial includes
3.2 mg of ibritumomab tiuxetan in 2 mL of 0.9% Sodium Chloride.
Physical/Radiochemical Characteristics of In-111
Indium-111 decays by electron capture, with a physical half-life of 67.3 hours
(2.81 days). The product of radioactive decay is non-radioactive Cadmium-111.
Radiation emission data for In-111 are summarized in Table 5.
Table 5 : Principal In-111 Radiation Emission Data



Radiation
Mean % per Disintegration
Mean Energy (keV)


Gamma-2
90.2
171.3


Gamma-3
94.0
245.4



External Radiation
The exposure rate constant for 1 mCi (37 MBq) of In-111 is 8.3 x 10-4 C/kg/hr
(3.2 R/hr) at 1 cm.
To allow correction for physical decay of In-111, the fractions that remain
at selected intervals before and after the time of calibration are shown in
Table 6.
Table 6 : Physical Decay Chart: In-111 Half-life 2.81 Days
(67.3 Hours)



Calibration Time
(Hrs.)
Fraction Remaining


-48
1.64


-42
1.54


-36
1.45


-24
1.28


-12
1.13


-6
1.06


0
1.00


6
0.94


12
0.88


24
0.78


36
0.69


42
0.65


48
0.61



Physical/Radiochemical Characteristics of Y-90
Yttrium-90 decays by emission of beta particles, with a physical half-life
of 64.1 hours (2.67 days). The product of radioactive decay is non-radioactive
Zirconium-90. The range of beta particles in soft tissue (χ90) is 5 mm.
Radiation emission data for Y-90 are summarized in Table 7.
Table 7 : Principal Y-90 Radiation Emission Data



Radiation
Mean % per
Disintegration
Mean Energy (keV)


Beta minus
100
750-935



External Radiation
The exposure rate for 1 mCi (37 MBq) of Y-90 is 8.3 x 10-3 C/kg/hr
(32 R/hr) at the mouth of an open Y-90 vial. To allow correction for physical
decay of Y-90, the fractions that remain at selected intervals before and after
the time of calibration are shown in Table 8.
Table 8 : Physical Decay Chart: Y-90 Half-life 2.67 Days
(64.1 Hours)



Calibration
Time (Hrs.)
Fraction
Remaining
Calibration Time
(Hrs.)
Fraction
Remaining


-36
1.48
0
1.00


-24
1.30
1
0.99


-12
1.14
2
0.98


-8
1.09
3
0.97


-7
1.08
4
0.96


-6
1.07
5
0.95


-5
1.06
6
0.94


-4
1.04
7
0.93


-3
1.03
8
0.92


-2
1.02
12
0.88


-1
1.01
24
0.77


0
1.00
36
0.68



Last reviewed on RxList: 9/18/2009




Zevalin Drug Description
ZEVALIN®
(ibritumomab tiuxetan) Injection for Intravenous Use

WARNING
SERIOUS INFUSION REACTIONS, PROLONGED AND SEVERE CYTOPENIAS,
and SEVERE CUTANEOUS AND MUCOCUTANEOUS REACTIONS
Serious Infusion Reactions: Deaths have occurred within 24 hours of rituximab
infusion, an essential component of the Zevalin therapeutic regimen. These fatalities
were associated with hypoxia, pulmonary infiltrates, acute respiratory distress
syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock.
Most (80%) fatalities
occurred with the first rituximab infusion [see WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS]. Discontinue rituximab, In-111
Zevalin, and Y-90 Zevalin infusions in patients who develop severe infusion
reactions.
Prolonged and Severe Cytopenias: Y-90 Zevalin administration results in
severe and prolonged cytopenias in most patients. Do not administer the Zevalin
therapeutic regimen to patients with ≥ 25% lymphoma marrow involvement and/or
impaired bone marrow reserve [see WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS].
Severe Cutaneous and Mucocutaneous Reactions: Severe cutaneous and mucocutaneous
reactions, some fatal, can occur with the Zevalin therapeutic regimen. Discontinue
rituximab, In-111 Zevalin, and Y-90 Zevalin infusions in patients experiencing
severe cutaneous or mucocutaneous reactions [see WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS].
Dosing: The dose of Y-90 Zevalin should not exceed 32.0 mCi (1184 MBq).
Do not administer Y-90 Zevalin to patients with altered biodistribution as determined
by imaging with In-111 Zevalin [see DOSAGE AND ADMINISTRATION].

DRUG DESCRIPTION



What are the possible side effects of ibritumomab (In-111 Zevalin, Y-90 Zevalin)?

Some people receiving an ibritumomab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, sweaty, itchy, or have a fast heartbeat, trouble breathing, chest pain or heavy feeling, or pain spreading to the arm or shoulder. These reactions can occur during the injection or within 24 hours afterward.
Get emergency medical help if you have any of these signs of an allergic...
Read All Potential Side Effects for Zevalin »




Zevalin (ibritumomab tiuxetan) is the immunoconjugate resulting from a stable
thiourea covalent bond between the monoclonal antibody ibritumomab and the linker-chelator
tiuxetan [N-[2-bis(carboxymethyl)amino]-3-(pisothiocyanatophenyl)- propyl]-[N-[2-bis(carboxymethyl)amino]-2-(methyl)-
ethyl]glycine. This linker-chelator provides a high affinity, conformationally
restricted chelation site for Indium-111 or Yttrium-90. The approximate molecular
weight of ibritumomab tiuxetan is 148 kD. The antibody moiety of Zevalin is
ibritumomab, a murine IgG1 kappa monoclonal antibody directed against the CD20
antigen.
Ibritumomab tiuxetan is a clear, colorless, sterile, pyrogen-free, preservativefree
solution that may contain translucent particles. Each single-use vial includes
3.2 mg of ibritumomab tiuxetan in 2 mL of 0.9% Sodium Chloride.
Physical/Radiochemical Characteristics of In-111
Indium-111 decays by electron capture, with a physical half-life of 67.3 hours
(2.81 days). The product of radioactive decay is non-radioactive Cadmium-111.
Radiation emission data for In-111 are summarized in Table 5.
Table 5 : Principal In-111 Radiation Emission Data



Radiation
Mean % per Disintegration
Mean Energy (keV)


Gamma-2
90.2
171.3


Gamma-3
94.0
245.4



External Radiation
The exposure rate constant for 1 mCi (37 MBq) of In-111 is 8.3 x 10-4 C/kg/hr
(3.2 R/hr) at 1 cm.
To allow correction for physical decay of In-111, the fractions that remain
at selected intervals before and after the time of calibration are shown in
Table 6.
Table 6 : Physical Decay Chart: In-111 Half-life 2.81 Days
(67.3 Hours)



Calibration Time
(Hrs.)
Fraction Remaining


-48
1.64


-42
1.54


-36
1.45


-24
1.28


-12
1.13


-6
1.06


0
1.00


6
0.94


12
0.88


24
0.78


36
0.69


42
0.65


48
0.61



Physical/Radiochemical Characteristics of Y-90
Yttrium-90 decays by emission of beta particles, with a physical half-life
of 64.1 hours (2.67 days). The product of radioactive decay is non-radioactive
Zirconium-90. The range of beta particles in soft tissue (χ90) is 5 mm.
Radiation emission data for Y-90 are summarized in Table 7.
Table 7 : Principal Y-90 Radiation Emission Data



Radiation
Mean % per
Disintegration
Mean Energy (keV)


Beta minus
100
750-935



External Radiation
The exposure rate for 1 mCi (37 MBq) of Y-90 is 8.3 x 10-3 C/kg/hr
(32 R/hr) at the mouth of an open Y-90 vial. To allow correction for physical
decay of Y-90, the fractions that remain at selected intervals before and after
the time of calibration are shown in Table 8.
Table 8 : Physical Decay Chart: Y-90 Half-life 2.67 Days
(64.1 Hours)



Calibration
Time (Hrs.)
Fraction
Remaining
Calibration Time
(Hrs.)
Fraction
Remaining


-36
1.48
0
1.00


-24
1.30
1
0.99


-12
1.14
2
0.98


-8
1.09
3
0.97


-7
1.08
4
0.96


-6
1.07
5
0.95


-5
1.06
6
0.94


-4
1.04
7
0.93


-3
1.03
8
0.92


-2
1.02
12
0.88


-1
1.01
24
0.77


0
1.00
36
0.68



Last reviewed on RxList: 9/18/2009




Zevalin Drug Description
ZEVALIN®
(ibritumomab tiuxetan) Injection for Intravenous Use

WARNING
SERIOUS INFUSION REACTIONS, PROLONGED AND SEVERE CYTOPENIAS,
and SEVERE CUTANEOUS AND MUCOCUTANEOUS REACTIONS
Serious Infusion Reactions: Deaths have occurred within 24 hours of rituximab
infusion, an essential component of the Zevalin therapeutic regimen. These fatalities
were associated with hypoxia, pulmonary infiltrates, acute respiratory distress
syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock.
Most (80%) fatalities
occurred with the first rituximab infusion [see WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS]. Discontinue rituximab, In-111
Zevalin, and Y-90 Zevalin infusions in patients who develop severe infusion
reactions.
Prolonged and Severe Cytopenias: Y-90 Zevalin administration results in
severe and prolonged cytopenias in most patients. Do not administer the Zevalin
therapeutic regimen to patients with ≥ 25% lymphoma marrow involvement and/or
impaired bone marrow reserve [see WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS].
Severe Cutaneous and Mucocutaneous Reactions: Severe cutaneous and mucocutaneous
reactions, some fatal, can occur with the Zevalin therapeutic regimen. Discontinue
rituximab, In-111 Zevalin, and Y-90 Zevalin infusions in patients experiencing
severe cutaneous or mucocutaneous reactions [see WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS].
Dosing: The dose of Y-90 Zevalin should not exceed 32.0 mCi (1184 MBq).
Do not administer Y-90 Zevalin to patients with altered biodistribution as determined
by imaging with In-111 Zevalin [see DOSAGE AND ADMINISTRATION].

DRUG DESCRIPTION



What are the possible side effects of ibritumomab (In-111 Zevalin, Y-90 Zevalin)?

Some people receiving an ibritumomab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, sweaty, itchy, or have a fast heartbeat, trouble breathing, chest pain or heavy feeling, or pain spreading to the arm or shoulder. These reactions can occur during the injection or within 24 hours afterward.
Get emergency medical help if you have any of these signs of an allergic...
Read All Potential Side Effects for Zevalin »




Zevalin (ibritumomab tiuxetan) is the immunoconjugate resulting from a stable
thiourea covalent bond between the monoclonal antibody ibritumomab and the linker-chelator
tiuxetan [N-[2-bis(carboxymethyl)amino]-3-(pisothiocyanatophenyl)- propyl]-[N-[2-bis(carboxymethyl)amino]-2-(methyl)-
ethyl]glycine. This linker-chelator provides a high affinity, conformationally
restricted chelation site for Indium-111 or Yttrium-90. The approximate molecular
weight of ibritumomab tiuxetan is 148 kD. The antibody moiety of Zevalin is
ibritumomab, a murine IgG1 kappa monoclonal antibody directed against the CD20
antigen.
Ibritumomab tiuxetan is a clear, colorless, sterile, pyrogen-free, preservativefree
solution that may contain translucent particles. Each single-use vial includes
3.2 mg of ibritumomab tiuxetan in 2 mL of 0.9% Sodium Chloride.
Physical/Radiochemical Characteristics of In-111
Indium-111 decays by electron capture, with a physical half-life of 67.3 hours
(2.81 days). The product of radioactive decay is non-radioactive Cadmium-111.
Radiation emission data for In-111 are summarized in Table 5.
Table 5 : Principal In-111 Radiation Emission Data



Radiation
Mean % per Disintegration
Mean Energy (keV)


Gamma-2
90.2
171.3


Gamma-3
94.0
245.4



External Radiation
The exposure rate constant for 1 mCi (37 MBq) of In-111 is 8.3 x 10-4 C/kg/hr
(3.2 R/hr) at 1 cm.
To allow correction for physical decay of In-111, the fractions that remain
at selected intervals before and after the time of calibration are shown in
Table 6.
Table 6 : Physical Decay Chart: In-111 Half-life 2.81 Days
(67.3 Hours)



Calibration Time
(Hrs.)
Fraction Remaining


-48
1.64


-42
1.54


-36
1.45


-24
1.28


-12
1.13


-6
1.06


0
1.00


6
0.94


12
0.88


24
0.78


36
0.69


42
0.65


48
0.61



Physical/Radiochemical Characteristics of Y-90
Yttrium-90 decays by emission of beta particles, with a physical half-life
of 64.1 hours (2.67 days). The product of radioactive decay is non-radioactive
Zirconium-90. The range of beta particles in soft tissue (χ90) is 5 mm.
Radiation emission data for Y-90 are summarized in Table 7.
Table 7 : Principal Y-90 Radiation Emission Data



Radiation
Mean % per
Disintegration
Mean Energy (keV)


Beta minus
100
750-935



External Radiation
The exposure rate for 1 mCi (37 MBq) of Y-90 is 8.3 x 10-3 C/kg/hr
(32 R/hr) at the mouth of an open Y-90 vial. To allow correction for physical
decay of Y-90, the fractions that remain at selected intervals before and after
the time of calibration are shown in Table 8.
Table 8 : Physical Decay Chart: Y-90 Half-life 2.67 Days
(64.1 Hours)



Calibration
Time (Hrs.)
Fraction
Remaining
Calibration Time
(Hrs.)
Fraction
Remaining


-36
1.48
0
1.00


-24
1.30
1
0.99


-12
1.14
2
0.98


-8
1.09
3
0.97


-7
1.08
4
0.96


-6
1.07
5
0.95


-5
1.06
6
0.94


-4
1.04
7
0.93


-3
1.03
8
0.92


-2
1.02
12
0.88


-1
1.01
24
0.77


0
1.00
36
0.68



Last reviewed on RxList: 9/18/2009




Zevalin Drug Description
ZEVALIN®
(ibritumomab tiuxetan) Injection for Intravenous Use

WARNING
SERIOUS INFUSION REACTIONS, PROLONGED AND SEVERE CYTOPENIAS,
and SEVERE CUTANEOUS AND MUCOCUTANEOUS REACTIONS
Serious Infusion Reactions: Deaths have occurred within 24 hours of rituximab
infusion, an essential component of the Zevalin therapeutic regimen. These fatalities
were associated with hypoxia, pulmonary infiltrates, acute respiratory distress
syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock.
Most (80%) fatalities
occurred with the first rituximab infusion [see WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS]. Discontinue rituximab, In-111
Zevalin, and Y-90 Zevalin infusions in patients who develop severe infusion
reactions.
Prolonged and Severe Cytopenias: Y-90 Zevalin administration results in
severe and prolonged cytopenias in most patients. Do not administer the Zevalin
therapeutic regimen to patients with ≥ 25% lymphoma marrow involvement and/or
impaired bone marrow reserve [see WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS].
Severe Cutaneous and Mucocutaneous Reactions: Severe cutaneous and mucocutaneous
reactions, some fatal, can occur with the Zevalin therapeutic regimen. Discontinue
rituximab, In-111 Zevalin, and Y-90 Zevalin infusions in patients experiencing
severe cutaneous or mucocutaneous reactions [see WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS].
Dosing: The dose of Y-90 Zevalin should not exceed 32.0 mCi (1184 MBq).
Do not administer Y-90 Zevalin to patients with altered biodistribution as determined
by imaging with In-111 Zevalin [see DOSAGE AND ADMINISTRATION].

DRUG DESCRIPTION



What are the possible side effects of ibritumomab (In-111 Zevalin, Y-90 Zevalin)?

Some people receiving an ibritumomab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, sweaty, itchy, or have a fast heartbeat, trouble breathing, chest pain or heavy feeling, or pain spreading to the arm or shoulder. These reactions can occur during the injection or within 24 hours afterward.
Get emergency medical help if you have any of these signs of an allergic...
Read All Potential Side Effects for Zevalin »




Zevalin (ibritumomab tiuxetan) is the immunoconjugate resulting from a stable
thiourea covalent bond between the monoclonal antibody ibritumomab and the linker-chelator
tiuxetan [N-[2-bis(carboxymethyl)amino]-3-(pisothiocyanatophenyl)- propyl]-[N-[2-bis(carboxymethyl)amino]-2-(methyl)-
ethyl]glycine. This linker-chelator provides a high affinity, conformationally
restricted chelation site for Indium-111 or Yttrium-90. The approximate molecular
weight of ibritumomab tiuxetan is 148 kD. The antibody moiety of Zevalin is
ibritumomab, a murine IgG1 kappa monoclonal antibody directed against the CD20
antigen.
Ibritumomab tiuxetan is a clear, colorless, sterile, pyrogen-free, preservativefree
solution that may contain translucent particles. Each single-use vial includes
3.2 mg of ibritumomab tiuxetan in 2 mL of 0.9% Sodium Chloride.
Physical/Radiochemical Characteristics of In-111
Indium-111 decays by electron capture, with a physical half-life of 67.3 hours
(2.81 days). The product of radioactive decay is non-radioactive Cadmium-111.
Radiation emission data for In-111 are summarized in Table 5.
Table 5 : Principal In-111 Radiation Emission Data



Radiation
Mean % per Disintegration
Mean Energy (keV)


Gamma-2
90.2
171.3


Gamma-3
94.0
245.4



External Radiation
The exposure rate constant for 1 mCi (37 MBq) of In-111 is 8.3 x 10-4 C/kg/hr
(3.2 R/hr) at 1 cm.
To allow correction for physical decay of In-111, the fractions that remain
at selected intervals before and after the time of calibration are shown in
Table 6.
Table 6 : Physical Decay Chart: In-111 Half-life 2.81 Days
(67.3 Hours)



Calibration Time
(Hrs.)
Fraction Remaining


-48
1.64


-42
1.54


-36
1.45


-24
1.28


-12
1.13


-6
1.06


0
1.00


6
0.94


12
0.88


24
0.78


36
0.69


42
0.65


48
0.61



Physical/Radiochemical Characteristics of Y-90
Yttrium-90 decays by emission of beta particles, with a physical half-life
of 64.1 hours (2.67 days). The product of radioactive decay is non-radioactive
Zirconium-90. The range of beta particles in soft tissue (χ90) is 5 mm.
Radiation emission data for Y-90 are summarized in Table 7.
Table 7 : Principal Y-90 Radiation Emission Data



Radiation
Mean % per
Disintegration
Mean Energy (keV)


Beta minus
100
750-935



External Radiation
The exposure rate for 1 mCi (37 MBq) of Y-90 is 8.3 x 10-3 C/kg/hr
(32 R/hr) at the mouth of an open Y-90 vial. To allow correction for physical
decay of Y-90, the fractions that remain at selected intervals before and after
the time of calibration are shown in Table 8.
Table 8 : Physical Decay Chart: Y-90 Half-life 2.67 Days
(64.1 Hours)



Calibration
Time (Hrs.)
Fraction
Remaining
Calibration Time
(Hrs.)
Fraction
Remaining


-36
1.48
0
1.00


-24
1.30
1
0.99


-12
1.14
2
0.98


-8
1.09
3
0.97


-7
1.08
4
0.96


-6
1.07
5
0.95


-5
1.06
6
0.94


-4
1.04
7
0.93


-3
1.03
8
0.92


-2
1.02
12
0.88


-1
1.01
24
0.77


0
1.00
36
0.68



Last reviewed on RxList: 9/18/2009




Zevalin Drug Description
ZEVALIN®
(ibritumomab tiuxetan) Injection for Intravenous Use

WARNING
SERIOUS INFUSION REACTIONS, PROLONGED AND SEVERE CYTOPENIAS,
and SEVERE CUTANEOUS AND MUCOCUTANEOUS REACTIONS
Serious Infusion Reactions: Deaths have occurred within 24 hours of rituximab
infusion, an essential component of the Zevalin therapeutic regimen. These fatalities
were associated with hypoxia, pulmonary infiltrates, acute respiratory distress
syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock.
Most (80%) fatalities
occurred with the first rituximab infusion [see WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS]. Discontinue rituximab, In-111
Zevalin, and Y-90 Zevalin infusions in patients who develop severe infusion
reactions.
Prolonged and Severe Cytopenias: Y-90 Zevalin administration results in
severe and prolonged cytopenias in most patients. Do not administer the Zevalin
therapeutic regimen to patients with ≥ 25% lymphoma marrow involvement and/or
impaired bone marrow reserve [see WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS].
Severe Cutaneous and Mucocutaneous Reactions: Severe cutaneous and mucocutaneous
reactions, some fatal, can occur with the Zevalin therapeutic regimen. Discontinue
rituximab, In-111 Zevalin, and Y-90 Zevalin infusions in patients experiencing
severe cutaneous or mucocutaneous reactions [see WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS].
Dosing: The dose of Y-90 Zevalin should not exceed 32.0 mCi (1184 MBq).
Do not administer Y-90 Zevalin to patients with altered biodistribution as determined
by imaging with In-111 Zevalin [see DOSAGE AND ADMINISTRATION].

DRUG DESCRIPTION



What are the possible side effects of ibritumomab (In-111 Zevalin, Y-90 Zevalin)?

Some people receiving an ibritumomab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, sweaty, itchy, or have a fast heartbeat, trouble breathing, chest pain or heavy feeling, or pain spreading to the arm or shoulder. These reactions can occur during the injection or within 24 hours afterward.
Get emergency medical help if you have any of these signs of an allergic...
Read All Potential Side Effects for Zevalin »




Zevalin (ibritumomab tiuxetan) is the immunoconjugate resulting from a stable
thiourea covalent bond between the monoclonal antibody ibritumomab and the linker-chelator
tiuxetan [N-[2-bis(carboxymethyl)amino]-3-(pisothiocyanatophenyl)- propyl]-[N-[2-bis(carboxymethyl)amino]-2-(methyl)-
ethyl]glycine. This linker-chelator provides a high affinity, conformationally
restricted chelation site for Indium-111 or Yttrium-90. The approximate molecular
weight of ibritumomab tiuxetan is 148 kD. The antibody moiety of Zevalin is
ibritumomab, a murine IgG1 kappa monoclonal antibody directed against the CD20
antigen.
Ibritumomab tiuxetan is a clear, colorless, sterile, pyrogen-free, preservativefree
solution that may contain translucent particles. Each single-use vial includes
3.2 mg of ibritumomab tiuxetan in 2 mL of 0.9% Sodium Chloride.
Physical/Radiochemical Characteristics of In-111
Indium-111 decays by electron capture, with a physical half-life of 67.3 hours
(2.81 days). The product of radioactive decay is non-radioactive Cadmium-111.
Radiation emission data for In-111 are summarized in Table 5.
Table 5 : Principal In-111 Radiation Emission Data



Radiation
Mean % per Disintegration
Mean Energy (keV)


Gamma-2
90.2
171.3


Gamma-3
94.0
245.4



External Radiation
The exposure rate constant for 1 mCi (37 MBq) of In-111 is 8.3 x 10-4 C/kg/hr
(3.2 R/hr) at 1 cm.
To allow correction for physical decay of In-111, the fractions that remain
at selected intervals before and after the time of calibration are shown in
Table 6.
Table 6 : Physical Decay Chart: In-111 Half-life 2.81 Days
(67.3 Hours)



Calibration Time
(Hrs.)
Fraction Remaining


-48
1.64


-42
1.54


-36
1.45


-24
1.28


-12
1.13


-6
1.06


0
1.00


6
0.94


12
0.88


24
0.78


36
0.69


42
0.65


48
0.61



Physical/Radiochemical Characteristics of Y-90
Yttrium-90 decays by emission of beta particles, with a physical half-life
of 64.1 hours (2.67 days). The product of radioactive decay is non-radioactive
Zirconium-90. The range of beta particles in soft tissue (χ90) is 5 mm.
Radiation emission data for Y-90 are summarized in Table 7.
Table 7 : Principal Y-90 Radiation Emission Data



Radiation
Mean % per
Disintegration
Mean Energy (keV)


Beta minus
100
750-935



External Radiation
The exposure rate for 1 mCi (37 MBq) of Y-90 is 8.3 x 10-3 C/kg/hr
(32 R/hr) at the mouth of an open Y-90 vial. To allow correction for physical
decay of Y-90, the fractions that remain at selected intervals before and after
the time of calibration are shown in Table 8.
Table 8 : Physical Decay Chart: Y-90 Half-life 2.67 Days
(64.1 Hours)



Calibration
Time (Hrs.)
Fraction
Remaining
Calibration Time
(Hrs.)
Fraction
Remaining


-36
1.48
0
1.00


-24
1.30
1
0.99


-12
1.14
2
0.98


-8
1.09
3
0.97


-7
1.08
4
0.96


-6
1.07
5
0.95


-5
1.06
6
0.94


-4
1.04
7
0.93


-3
1.03
8
0.92


-2
1.02
12
0.88


-1
1.01
24
0.77


0
1.00
36
0.68



Last reviewed on RxList: 9/18/2009





Other reviews about Zevalin on wordpress

Non-Hodgkin's Lymphoma
  by sscooter
What is Non-Hodgkin's Lymphoma (NHL)?  Well, it is one of the most common cancers in the United States and ranks as the 5th most common. Approximately 50,000 cases […]


Non-Hodgkins Lymphoma Treatment
  by sscooter
This is from a press release concerning Zevalin.  Apparently the University of Pittsburgh has released findings that Zevalin may be effective is treating Non-Hodgkin's lymphoma patients with advanced […]


Yanking the Cure Rug Out From Under Lymphoma Patients
  by AdvoConnection
In the continuing saga of two "miracle" drugs for those who suffer from non-Hodgkins lymphomas... the fifth most common cancer.... I told you six months ago about Bexxar […]


Zevalin Consolidation In Patients With Complete Remission After Induction Therapy Results In Durable Remission Of More Than 67 Months
  by yestelli
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that extended follow-up data for the Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent (FIT) study presented at the American Society of […]


ZEVALIN(R) Produced 83 Percent Complete Response Rate In Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma Study
  by enartion
Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI) announced results of a study published by Esmaeli, et al. online on January 15, 2009 in the Annals of Oncology demonstrating that rituximab followed […]


M&A Update 2
  by Jeremy G
Here's the latest collection of M&A news we've found since the last update.  No new mega-deals, although Sanofi is shopping in the €15 billion range and Roche sold […]


Spectrum Pharmaceuticals to Benefit from FDA Action on Zevalin?
  by Michael Becker
By Michael D. Becker According to the American Cancer Society [ACS], non-Hodgkin lymphoma [also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma] is a cancer that starts in […]


Spectrum Pharmaceuticals Submitted Formal Response to FDA Complete Response Letter on Wednesday, July 8, 2009
  by Biotechtrader
ZEVALIN Supplemental Biologics License Application is Currently Under Review by the FDA for Use in the First-Line Consolidation Setting for Non-Hodgkin’s Lymphoma (NHL) Patients ZEVALIN is Currently FDA Approved […]


Bayer’s Bold New Bet Fails to Rain on Spectrum Pharmaceuticals
  by Michael Becker
By Michael D. Becker Despite recent progress and the availability of novel therapies, radiation is still an effective tool in the war against cancer – as it has been […]



Other reviews about Zevalin on web:

ZEVALIN (ibritumomab tiuxetan) from Spectrum Pharmaceuticals is a CD20-directed radiotherapeutic antibody. Learns more about Zevalin. ZEVALIN® (ibritumomab tiuxetan) ll Official Site


Ibritumomab tiuxetan, sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for some forms of B cell non-Hodgkin's lymphoma, a ... Ibritumomab tiuxetan - Wikipedia, the free encyclopedia


Learn about the prescription medication Zevalin (Ibritumomab Tiuxetan), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Zevalin (Ibritumomab Tiuxetan) Drug Information: Uses, Side ...


Information on Zevalin / 90 ibritumomab tiuxetan - a monoclonal antibody chemotherapy for Non-Hodgkin's Lymphoma Monoclonal Antibody Therapy: Zevalin


Accurate, FDA approved Zevalin information for healthcare professionals and patients - brought to you by Drugs.com. Zevalin Official FDA information, side effects and uses.


warning: serious infusion reactions, prolonged and severe cytopenias, and severe cutaneous and mucocutaneous reactions zevalin bla 125019 Zevalin BLA 125019


Comparing Properties of Bexxar & Zevalin. Patients often ask us: Which of these agents is better? Because Zevalin and Bexxar have not been compared head-to ... Bexxar vs. Zevalin


Zevalin is the trade name for the generic chemotherapy drug Ibritumomab. Zevalin is a monoclonal antibody that is linked with a radioactive substance Yttrium-90. Zevalin is ... Zevalin, Ibritumomab, Ibritumomab Tiuxetan - Chemotherapy Drugs ...


Treatment Overview > Zevalin. Last update: 08/26/2010: TOPICS Intro | How is Zevalin Given? Resources | News and Abstracts Zevalin


Zevalin is a type of radioimmunotherapy drug that's used for some types of non-Hodgkin lymphoma (NHL). It is often given to patients who whose cancer has come back, or who have ... Zevalin -- Drug Treatment for Non-Hodgkin Lymphoma -- Ibritumomab ...





Featured Reviews

Reviews Cyklokapron

Cyklokapron Drug Description Cyklokapron® (tranexamic acid) Injection Antifibrinolytic agent DRUG DESCRIPTION What are the possible side effects of tranexamic acid (Cyklokapron)? Get emergency medical help if you have any...
Read More  |  Review This
Reviews Clurandrenolide Cream

Cordran Cream Drug Description Cordran® SP (flurandrenolide) Cream Cordran® (flurandrenolide) Ointment DRUG DESCRIPTION Cordran® (Flurandrenolide, USP) is a potent corticosteroid intended for topical use. Flurandrenolide...
Read More  |  Review This
Reviews Oxazepam

Serax Drug Description Serax® (oxazepam) Capsules and Tablets DRUG DESCRIPTION What are the possible side effects of oxazepam (Serax)? Get emergency medical help if you have any of these signs of an allergic reaction: hives;...
Read More  |  Review This
Reviews Estradiol, Norgestimate

Prefest Drug Description PREFEST™ (estradiol/norgestimate) Tablets WARNING Estrogens and progestins should not be used for the prevention of cardiovascular disease. (See WARNINGS, Cardiovascular disorders.) The Women's Health...
Read More  |  Review This
Reviews Yohimbine

Aphrodyne Drug Description DRUG DESCRIPTION Yohimbine is a 3a-15a-20(beta)-17a- hydroxy Yohimbine-16a-carboxylic acid methyl ester. The alkaloid is found in Rubaceae and related trees and is also found in Rauwolfia Serpentina (L) Benth....
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....